Back to Search
Start Over
Avacopan for ANCA-associated vasculitis – information for prescribers.
- Source :
-
Nephrology Dialysis Transplantation . May2023, Vol. 38 Issue 5, p1067-1070. 4p. - Publication Year :
- 2023
-
Abstract
- The approval of avacopan as a treatment for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by the US Food and Drug Administration (FDA) in 2021 and the European Medicines Agency (EMA) in 2022 represents an important therapeutic advance. Of the patients receiving avacopan, 13.3% suffered serious infections versus 15.2% in those in the prednisone group, and serious opportunistic infections were less common in patients receiving avacopan (3.6% in the avacopan group, 6.7% in the prednisone group) [[10]]. Insights from the ADVOCATE study: respiratory tract involvement in patients with ANCA-associated vasculitis in a randomized, double-blind, placebo-controlled, phase 3 trial of avacopan. Recovery of renal function among ANCA-associated vasculitis patients with baseline eGFR <=20 in the avacopan ADVOCATE trial. [Extracted from the article]
- Subjects :
- *VASCULITIS
*MICROSCOPIC polyangiitis
Subjects
Details
- Language :
- English
- ISSN :
- 09310509
- Volume :
- 38
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Nephrology Dialysis Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 163536611
- Full Text :
- https://doi.org/10.1093/ndt/gfac330